Akero presents phase 2b results and SYNCHRONY trial at SOLAR Conference
The poster highlights efruxifermin in MASH and ongoing phase 3 enrollment for F2/F3 to compensated cirrhosis.
Latest Akero Therapeutics News & Updates
See the latest news and media coverage for Akero. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing MASH therapies
akerotx.com- Headquarters
- South San Francisco, United States
- Founded year
- 2017
- Company type
- Public company
- Number of employees
- 10–80
- Industry
- Pharmaceuticals
Last updated
Latest news about Akero Therapeutics (Akero)
In short: Akero was acquired by Novo Nordisk for up to $5.2 billion to advance efruxifermin (EFX) for treating metabolic disease and MASH.
Company announcements
Akero Therapeutics reflects on 2025 achievements
They showed cirrhosis reversal in Phase 2b trial, completed Phase 3 enrollment, and finalized Novo Nordisk acquisition. They anticipate 2026 progress.
Akero Therapeutics completes acquisition by Novo Nordisk
This milestone advances efruxifermin for MASH treatment, complementing Novo Nordisk's metabolic disease portfolio.
Akero Therapeutics shares new efruxifermin data at AASLD
They present posters and oral sessions on antifibrotic activity from SYMMETRY and HARMONY trials.
Media coverage
Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion
Under the terms of the deal, Novo Nordisk will initially pay $54 a share in cash, or $4.7 billion, upon closing. Akero shareholders will also...
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics | PharmExec
Novo Nordisk acquires Akero Therapeutics to enhance its portfolio with efruxifermin, a promising treatment for metabolic dysfunction-associated steatohepatitis.
What Drove Avoro Capital Advisors' Strategic Exit from Akero Therapeutics
Avoro Capital Advisors sold its entire stake in Akero Therapeutics for $187.81 million. This strategic exit followed Novo Nordisk's $5.2 billion acquisition of Akero. The...
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero ...
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale...
Never miss news about Akero
Track Akero and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Akero competitors & trending companies
Browse news for competitors to Akero and other trending companies.
Novo Nordisk
Chemomab
Viking Therapeutics
Can-Fite
Altimmune
Gilead
Ochre
VTX
AITX
Amrize
Advocate Health
Arconic
ARDG
Ashland
LB Pharmaceuticals
Gossamer Bio
USAR
Simpson Strong‑Tie
Celestica
Capricor
MediaAlpha
3D Systems
Generate:Biomedicines
FutureFuel
WisdomTree
Celeris
Coupang
LiveWire
Fermi
Science
Biglari Holdings Inc.
Pega
Global Self Storage
Utz